Elevance Health, Inc. (ELV) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This summary covers Elevance Health, Inc.'s Form 10-Q for the quarterly period ended September 30, 2024. Elevance is one of the largest U.S. health insurers, serving nearly 46 million medical members through affiliated health plans. The company operates through four reportable segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. The reporting period reflects ongoing Medicaid eligibility redeterminations, strategic acquisitions, and the divestiture of the life and disability businesses.
Key Financial Metrics
| Metric (in millions, except per share) | Q3 2024 | Q3 2023 | YTD 9M 2024 | YTD 9M 2023 |
|---|---|---|---|---|
| Total Operating Revenue | $44,719 | $42,480 | $130,215 | $127,755 |
| Net Income | $1,008 | $1,300 | $5,558 | $5,160 |
| Shareholders' Net Income | $1,016 | $1,289 | $5,562 | $5,131 |
| Diluted EPS | $4.36 | $5.45 | $23.81 | $21.56 |
| Operating Cash Flow (9M) | $5,102 | $11,032 | $5,102 | $11,032 |
| Cash & Equivalents | $7,866 | $6,526 | $7,866 | $6,526 |
| Total Debt (Short + Long Term) | $27,148 | $24,870 | $27,148 | $24,870 |
| Debt-to-Capital Ratio | 38.2% | 38.9% | 38.2% | 38.9% |
Note: Total Debt calculated as Short-term borrowings ($360) + Current portion of long-term debt ($2,100) + Long-term debt ($24,688).
Material Changes vs. Prior Period
- Revenue Growth: Operating revenue increased 5.3% in Q3 and 1.9% YTD, driven by premium rate increases across all lines of business and growth in CarelonRx product revenue. This was partially offset by a 19.0% decline in Medicaid membership due to eligibility redeterminations.
- Profitability Decline (Q3): Net income decreased 22.5% in Q3 2024 compared to Q3 2023. This was primarily due to a decrease in operating gain within reportable segments and a $39 million reduction in the gain on the sale of life and disability businesses due to contingent purchase price adjustments.
- Profitability Increase (YTD): Net income increased 7.7% YTD, supported by higher net investment income, a $201 million gain on the sale of the life and disability business, and lower amortization of intangible assets.
- Benefit Expense Ratio: The ratio increased to 89.5% in Q3 (from 86.8% in Q3 2023) and 87.2% YTD (from 86.3% YTD 2023). This increase is attributed to Medicaid rates being inadequate to cover medical cost trends, exacerbated by a shift in the Medicaid membership mix.
- Membership Trends: Total medical membership declined 3.3% to 45.76 million. Medicaid membership dropped by 2.09 million, while Individual membership grew by 30.0%.
Guidance, Outlook, and Risks
- Star Ratings Impact: The company expects a reduction in 2026 operating revenue of approximately $183 million due to 2025 Medicare Advantage Star Ratings (38% of members in 4.0+ star plans), down from the original 2024 rating of 53%. Management plans to mitigate this through contract diversification and expense efficiencies.
- Regulatory Environment: Continued Medicaid eligibility redeterminations are expected to drive membership attrition, though the company anticipates growth in commercial plans as members transition from Medicaid. The expiration of enhanced Premium Tax Credits at the end of 2025 remains a regulatory uncertainty.
- Legal Contingencies:
- BCBSA Antitrust Litigation: A settlement with provider plaintiffs is pending court approval, with Elevance's estimated share of the payment at $666 million, recognized as an operating expense in Q3 2024.
- Medicare Risk Adjustment: The DOJ lawsuit regarding alleged false certification of diagnosis data remains ongoing with fact discovery scheduled through 2025.
- Capital Allocation: On October 15, 2024, the Board authorized an additional $8 billion for share repurchases, bringing the total available to $11.1 billion. The quarterly dividend was maintained at $1.63 per share.
Investor Verification Checklist
- Medicaid Mix Impact: Verify the sustainability of the benefit expense ratio given the shift in Medicaid membership mix and the adequacy of current premium rates to cover medical cost trends.
- Star Rating Financials: Assess the specific strategies and timeline for mitigating the projected $183 million revenue reduction in 2026 related to Medicare Advantage Star Ratings.
- Legal Accruals: Confirm the final court approval and payment terms of the $666 million BCBSA Provider Settlement Agreement.
- Investment Portfolio: Review the composition of fixed maturity securities and the impact of interest rate fluctuations on net investment income and unrealized gains/losses.
- Acquisition Integration: Monitor the integration progress and financial contribution of recent acquisitions (Paragon, Mosaic Health joint venture) and pending deals (Centers, CareBridge).